World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 3.454
Year - 2023
Volume: 2; Issue: 6
Page: 99-111

A COMPREHENSIVE REVIEW OF ALZHEIMER'S DISEASE: PATHOGENESIS, RISK FACTORS, AND THERAPEUTIC APPROACHES

Reyam Ibraheem Daham[1], Ola Hatif Hazim[2*], Maysam Ihsan Ali Al-Hassany[3]

[1,2,3]Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.

Article Received: 09 August 2023 || Article Revised: 30 September 2023 || Article Accepted: 26 November 2023

Corresponding Author: Ola Hatif Hazim
Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.

ABSTRACT

This article examines Alzheimer's disease, a prevalent form of dementia that has increasingly become a significant public health concern as the aging population grows. The discussion commences by elucidating the discovery of Alzheimer's disease and identifying specific brain proteins that serve as indicative markers for the disease. The progression of the disease and the diverse array of factors that can influence its development are expounded upon. Alzheimer's disease risk factors include genetics, environment, lifestyle, and other medical conditions. The disease presents early cognitive and behavioral symptoms. Diagnosis involves a comprehensive approach utilizing medical history, physical exams, tests, and neuroimaging scans. Subsequently, the article delves into current therapeutic interventions for Alzheimer's, encompassing pharmacological interventions aimed at symptom management and non-pharmacological strategies like cognitive exercises, physical activity, and support systems for caregivers. Additionally, emerging treatment modalities are mentioned, including immunotherapy, gene therapy, stem cell-based approaches for neural tissue repair, personalized treatment based on genetic profiles, and the integration of various therapeutic approaches. Lastly, the article addresses preventive measures for Alzheimer's disease, advocating for regular exercise, a balanced diet, cognitive engagement, social interaction, cardiovascular health promotion, optimal sleep patterns, continuous monitoring of brain health, lifelong learning practices, and managing additional risk factors. The concluding remarks underscore the significance of early detection and timely intervention in managing Alzheimer's disease and call for further research to enhance treatment options and preventive strategies. Ultimately, the article instills hope for a future where Alzheimer's exerts less impact on individuals and society.

1. INTRODUCTION

Alzheimer's disease represents a profound global health concern that impacts a substantial proportion of individuals who have dementia. This neurological disorder manifests as a progressive deterioration in cognitive functions, memory retention, and the capacity to execute routine activities of daily living. The seminal identification of this debilitating condition traces back to the groundbreaking work of Dr. Alois Alzheimer, a prominent German physician, who, more than a century ago, astutely observed anomalous alterations within a patient's cerebral architecture that correlated with the emergence of distressing symptoms characterized by memory impairment, linguistic challenges, and erratic behavioral patterns. Following the unfortunate demise of the patient, Dr. Alzheimer meticulously conducted an in-depth post-mortem examination of her cerebral structures. He found two abnormalities we still associate with Alzheimer's today - build-ups of amyloid plaques outside brain cells and tangled bundles of fibers within brain cells.[1-3]

Even though there has been much research, we still do not know exactly what causes Alzheimer's. There are several theories, including the idea that it is caused by a build-up of certain proteins in the brain or that it is caused by inflammation, oxidative stress, or problems with blood vessels. However, it is probably caused by a combination of these factors. Many different things can increase your risk of getting Alzheimer's. Age is the biggest one - once you reach 65, your risk doubles every five years. Certain genes can also increase your risk. Certain risk factors for Alzheimer's disease can be influenced. These include health conditions like high blood pressure, diabetes, and obesity; lifestyle habits such as lack of physical activity or smoking; and social factors like depression and social isolation. Diagnosing Alzheimer's can be challenging because it develops slowly and worsens over time. Medical practitioners employ a comprehensive approach to diagnosing Alzheimer's disease, encompassing an amalgamation of crucial components such as an analysis of the patient's medical history, meticulous physical examinations, cognitive assessments, and neuroimaging techniques. Nevertheless, a definitive diagnosis commonly necessitates the meticulous examination of postmortem brain specimens. Present therapeutic interventions for Alzheimer's are primarily oriented towards enhancing cognitive functions and impeding the advancement of the ailment; regrettably, they fail to reverse the deleterious effects inflicted upon cerebral neurons entirely. Therefore, there is a strong focus on finding new treatments that can alter the course of the disease.[4,5]

Exciting advances have been made in utilizing the body's immune system, genetic modifications, and stem cell therapy to combat Alzheimer's and repair brain damage. Additionally, evidence is growing that lifestyle changes and addressing other risk factors can significantly reduce the risk of Alzheimer's.[6]

This scholarly article's primary objective is to comprehensively elucidate the multifaceted aspects of Alzheimer's disease, encompassing its pathogenesis, temporal evolution, diagnostic methodologies, and therapeutic interventions. The overarching aspiration is to foster a profound comprehension of this intricate disorder, ultimately facilitating the pursuit of efficacious treatment modalities that may ameliorate the burden imposed by this formidable affliction.

2. Brief History of Alzheimer’s Disease

In the annals of medical history, over a century ago, the diligent investigations of Dr. Alois Alzheimer initiated a seminal exploration into a pathological condition that would eventually be designated as Alzheimer's disease. His clinical encounters with Auguste Deter, a patient beset by debilitating symptoms encompassing profound memory impairment, linguistic challenges, and aberrant conduct, propelled Dr. Alzheimer toward an unwavering quest for knowledge. Through a postmortem examination of Ms. Deter's cerebral structures, Dr. Alzheimer made groundbreaking observations, elucidating two distinct forms of neuropathological damage. Specifically, he discerned the presence of amyloid plaques, deleterious accumulations of proteinaceous aggregates located extracellularly, as well as intracellularly situated neurofibrillary tangles characterized by intricate entanglements of fiber bundles comprised of abnormal tau protein.[7] Initially, not many people paid attention to Dr. Alzheimer's findings. However, around 60 years later, in the early 1970s, people started recognizing that Alzheimer's disease was the leading cause of dementia. This was partly because advancements allowed for easier visualization of amyloid plaques and tau tangles in the brains of individuals who had passed away from Alzheimer's.[8] In the 1980s, scientists identified a small protein called beta-amyloid as the main component of amyloid plaques. This led to the belief that beta-amyloid accumulation in the brain is the primary cause of Alzheimer's. Later studies revealed that beta-amyloid is produced from a larger protein, and specific changes in the gene responsible for this protein can result in a form of Alzheimer's that runs in families.[9] During the 1990s, scientists discovered additional genes associated with Alzheimer's. Changes in these genes can lead to most cases of familial Alzheimer's. Around the same time, they also found that a particular version of another gene significantly increases the risk of developing the most common type of Alzheimer's.[10] In the late 1900s, there were big advances in brain imaging techniques like CT, MRI, and PET scans. These tools let doctors look at the structure and function of the brain in living people, which has dramatically improved our ability to diagnose and study Alzheimer's. Despite these advances, there are not many treatment options for Alzheimer's. The drugs approved by the US FDA can temporarily improve thinking skills, but they do not stop the damage to brain cells. In contrast, the 21st century has seen much progress in understanding how Alzheimer's works. Research has expanded to include other aspects like tau pathology, inflammation, oxidative stress, problems with nerve cell connections, and vascular factors.[11] There is also a growing understanding that Alzheimer's is a complicated disease that probably involves a combination of genetic factors, environmental factors, lifestyle factors, and aging-related processes. Several extensive studies are underway to try to understand these complex relationships and find potential targets for treatment.[12]

3. Epidemiology of Alzheimer's Disease

Alzheimer's disease is the most common type of dementia worldwide, making up about 60-80% of all cases. It's a big public health problem, especially as people are living longer and the population is getting older. The World Health Organization estimates that around 50 million people around the world have dementia, with almost 10 million new cases each year, and most of these are Alzheimer's. In the United States alone, it's estimated that 5.8 million people aged 65 and older had Alzheimer's in 2020. This number is expected to almost triple to 14 million by 2060 as the population gets older. The risk of getting Alzheimer's also increases with age, doubling about every five years after age 65. Although getting Alzheimer's isn't a normal part of aging, age is still the biggest known risk factor for the disease. The prevalence of AD also varies by sex, with women being more affected than men. Almost two-thirds of Americans with AD are women. According to the Alzheimer's Association, a woman in her 60s has a 1 in 5 chance of developing AD during her remaining life, compared to a 1 in 11 chance for a man.[2]

AD also disproportionately impacts racial and ethnic groups. In the United States, older African Americans are about twice as likely to have AD or other forms of dementia as older Caucasians, and Hispanics are about one and one-half times as likely. On a global scale, the distribution of AD is uneven. Higher rates are found in developed regions such as North America and Western Europe compared to developing regions like Africa and Asia. However, these differences may reflect disparities in access to healthcare and diagnostic services rather than true variations in disease occurrence.[13]

The economic impact of AD is also substantial and increasing. In 2020, the total lifetime cost of care for someone with dementia was estimated at $373,527 in the United States. The total direct cost to American society of caring for those with Alzheimer's and other dementias is estimated at $355 billion in 2021, not including the value of unpaid caregiving. The mortality associated with AD is significant. It is the sixth-leading cause of death in the United States and the fifth-leading cause among those aged 65 and older. People with AD live on average four to eight years after diagnosis, but some live as long as 20 years, depending on other factors affecting their health.[14]

Despite these alarming statistics, some evidence suggests stabilization or even decline in the incidence rates (new cases per population in a specific period) of dementia in some high-income countries over the past few decades. These trends reflect improvements in brain health related to better education and living conditions and cardiovascular health, among other factors.

It is worth noting that many people with AD remain undiagnosed. Less than half of those with the disease are formally diagnosed by a healthcare provider, and among those diagnosed, only one-third are aware of their diagnosis. This under-diagnosis represents a significant barrier to providing appropriate care and support to individuals with AD and their caregivers.[15-16]

In summary, Alzheimer's disease represents a major public health challenge set to grow in the coming decades due to population aging. Knowing how Alzheimer's disease spreads and affects different groups of people can help organize healthcare resources and create plans for preventing the disease, detecting it early, and treating it.

4. Pathogenesis of Alzheimer's Disease

Scientists have been studying Alzheimer's disease for a long time to understand how it develops. They discovered certain signs in the brain, like amyloid plaques and neurofibrillary tangles, discovered by Alois Alzheimer in 1906. However, they are still trying to figure out exactly how these signs cause the brain to deteriorate and lead to problems with thinking and memory.[7]

4.1 Amyloid-beta Hypothesis

The main idea behind the amyloid-beta (Aβ) hypothesis is that the build-up of certain substances called Aβ peptides in the brain is the main cause of brain damage in Alzheimer's disease. These Aβ peptides come from a larger protein called amyloid precursor protein (APP). When certain enzymes break down APP, the Aβ peptides are formed. These peptides can stick together to form harmful clusters known as soluble oligomers, believed to be the most damaging form. Over time, these clusters can form insoluble amyloid plaques in the brain.[17,18]

Several lines of evidence support the Aβ hypothesis. First, mutations in the APP gene or the genes encoding the components of gamma-secretase (PSEN1 and PSEN2) cause familial AD, and these mutations often lead to increased production or aggregation of Aβ. Second, individuals with Down syndrome, who have an extra copy of the APP gene due to trisomy of chromosome 21, almost universally develop AD pathology by middle age. Lastly, Aβ oligomers have been found to impair synaptic function and plasticity in experimental models.[19]

Despite these supporting data, the Aβ hypothesis has been challenged by several observations. Many older adults have a significant amyloid plaque burden yet do not exhibit cognitive impairment, suggesting that Aβ accumulation is insufficient to cause dementia. Furthermore, clinical trials targeting Aβ—either by preventing its formation, promoting its clearance, or preventing its aggregation—have largely failed to halt cognitive decline in AD patients.[9]

4.2 Tau Hypothesis

The tau hypothesis provides another perspective on AD pathogenesis. It suggests that hyperphosphorylation of tau proteins leads to the formation of neurofibrillary tangles, which disrupt neuronal function and lead to cell death. *Tau* is a microtubule-associated protein that helps stabilize microtubules in neurons. However, in AD, tau becomes hyperphosphorylated and aggregates into paired helical filaments, the main component of neurofibrillary tangles.[20]

Support for the tau hypothesis comes from the strong correlation between tangle burden and degree of cognitive impairment in AD patients, a stronger correlation than that with amyloid plaque burden. Moreover, mutations in the tau gene cause frontotemporal dementia, demonstrating that tau dysfunction alone can drive neurodegeneration. Nevertheless, how tau pathology interacts with Aβ pathology remains a topic of ongoing research. Some evidence suggests that Aβ accumulation may trigger tau hyperphosphorylation and subsequent tangle formation, linking the two pathologies.[21]

4.3 Inflammation and Alzheimer’s

In recent years, inflammation has emerged as a key player in AD pathogenesis. Microglia, the resident immune cells of the brain, are found to surround amyloid plaques in AD brains. These activated microglia release inflammatory molecules that can damage neurons. Furthermore, genetic studies have identified several risk genes for AD involved in immune response, such as TREM2 and CD33, highlighting the role of inflammation in the disease.[22]

4.4 Neurovascular Hypothesis

The neurovascular hypothesis posits that cerebrovascular abnormalities precede and contribute to the pathogenesis of Alzheimer's disease (AD), exerting deleterious effects on brain cells. This hypothesis is substantiated by the observation that risk factors associated with vascular impairments, such as hypertension, diabetes mellitus, and obesity, also confer heightened susceptibility to AD. In individuals afflicted with AD, the cerebral vasculature frequently exhibits an accumulation of amyloid-beta (Aβ) within the vessel walls. At the same time, the integrity of the blood-brain barrier may be compromised.[23] While these findings provide valuable insights into the etiology of AD, it is essential to acknowledge that the disease likely arises from a multifactorial interplay of various elements. These elements encompass Aβ, tau pathology, neuroinflammation, cerebrovascular dysfunction, and additional factors. Elucidating the intricate interactions between these contributory factors is paramount in identifying efficacious therapeutic interventions for this devastating neurodegenerative disorder.[24]

5. Risk Factors for Alzheimer’s Disease

Alzheimer's disease (AD) represents a complex ailment characterized by many etiological influences. While advancing age constitutes the primary risk factor, numerous other determinants, including genetic predisposition, environmental factors, and lifestyle choices, play contributory roles. By comprehensively understanding these risk factors, we can gain valuable insights into the mechanisms underpinning AD pathogenesis and explore preventive strategies.[4,12]

5.1 Genetic Factors

Genetic factors exert a substantial influence on the development of Alzheimer's disease (AD). Notably, mutations occurring within three specific genes - amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) - can engender a rare form of AD that typically emerges before the age of 65 and displays familial clustering.

These mutations often result in the overproduction or aggregation of amyloid-beta (Aβ), a significant component of the detrimental amyloid plaques characteristic of AD neuropathology.[10,25]

Conversely, the most prominent genetic risk factor for the more prevalent late-onset form of AD is a polymorphic variant known as the ε4 allele of the apolipoprotein E (APOE) gene. Individuals harboring this variant face an elevated risk of developing AD and may exhibit an earlier age at onset. However, it is crucial to note that not all individuals possessing the ε4 allele will inevitably develop AD. Conversely, many individuals with AD do not possess this genetic variant, implying the involvement of additional contributory factors in disease manifestation. In recent years, scientists have used large studies to examine the entire genome and found many more genetic variations that increase the risk of getting AD. Many of these variations are in genes related to the immune system and how the body handles fats, which gives us new ways to understand what causes the disease.[26]

5.2 Environmental Factors

Some environmental factors are linked to the risk of getting Alzheimer's disease (AD). For instance, breathing in air pollution, especially tiny particles called PM2.5, and being around traffic-related air pollution have been connected to a higher risk of AD and problems with thinking. Other environmental factors, like exposure to heavy metals, pesticides, and electromagnetic fields, have been suggested as possible risks but need more research.[27]

5.3 Lifestyle Factors

Several lifestyle factors have been implicated in AD. Physical inactivity is a significant modifiable risk factor for the disease. Regular physical exercise benefits brain health through various mechanisms, including improved cardiovascular health, increased brain-derived neurotrophic factor (BDNF), and reduced Aβ deposition. Diet is another key modifiable risk factor. Diets high in saturated fats and sugars, such as the Western diet, are associated with increased AD risk, while diets rich in fruits, vegetables, whole grains, lean protein, and healthy fats, such as the Mediterranean diet, are associated with reduced risk. Not getting enough sleep or having sleep problems like insomnia and sleep apnea are now seen as risk factors for Alzheimer's disease (AD). When you don't get enough sleep for a long time or have sleep disorders, it can cause more of the substance called Aβ to be produced in the brain and make it harder for the brain to get rid of Aβ.[28,29]

6. Clinical Presentation and Diagnosis

Alzheimer's disease (AD) manifests as a gradual and progressive decline in cognitive function. The initial indication often presents as memory impairment, specifically challenges in recollecting recent events or acquiring new information. This phenomenon arises due to the pathological involvement of the medial temporal lobe, a crucial brain region responsible for forming fresh memories. As the disease advances, it extends its impact to encompass various memory domains. Individuals affected by AD may encounter difficulties retaining factual knowledge or abstract concepts (semantic memory) and obstacles in executing learned skills and routines (procedural memory). AD affects memory and language, object/facial recognition, planning/problem-solving, and mood/behavior. In later stages, individuals who rely on others for daily tasks experience eating/bladder issues, mobility difficulties, and cognitive impairment affecting time/place recognition and communication.[30,31]

Diagnosis[32,33]

The diagnostic process for Alzheimer's disease (AD) involves:

1. **Thorough assessment of medical history**: Medical professionals conduct a comprehensive evaluation of the patient's medical background, including symptoms, family history of dementia, and concurrent medical conditions. Input from family members or caregivers is valuable when individuals with AD lack insight into their cognitive difficulties.
2. **Comprehensive physical examination**: A meticulous physical exam is performed to rule out other potential causes of cognitive impairments.
3. **Administration of cognitive testing**: Standardized tests evaluate various cognitive domains, such as memory, language, attention, and problem-solving abilities. These tests help establish a comprehensive cognitive profile.
4. **Laboratory Investigations**: Blood tests are performed to eliminate other medical conditions that may give rise to cognitive disturbances, thus enabling clinicians to focus specifically on AD as the primary causative factor.
5. **Neuroimaging Techniques**: Brain imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI) are employed to identify structural alterations within the brain that may indicate AD pathology. Advanced imaging techniques such as positron emission tomography (PET) enable visualization of specific substances associated with AD pathology.
6. **Analysis of Cerebrospinal Fluid:** Lumbar puncture is utilized to obtain cerebrospinal fluid samples, which can subsequently be subjected to laboratory analysis to identify specific proteins that serve as biomarkers for AD pathology. This diagnostic approach aids in confirming the presence of AD-related abnormalities within the central nervous system.

AD diagnosis is usually based on clinical evaluation, but a definitive diagnosis requires examining brain tissue after death. However, clinical diagnosis is generally accurate when following established criteria in specialized memory clinics. Early diagnosis of AD allows for planning, accessing treatments, and participating in clinical trials. It also helps individuals and families make decisions about care and legal matters while the person with AD can still be involved.[33]

7. Current Therapeutic Approaches

Alzheimer’s disease (AD) currently has no cure, and available treatments primarily focus on managing symptoms and slowing disease progression. While these therapies cannot reverse the underlying neurodegeneration, they can provide some relief and improve the quality of life for patients and caregivers. The main therapeutic approaches for AD include pharmacological interventions and non-pharmacological interventions.[34]

7.1 Pharmacological Interventions

7.1.1 Cholinesterase Inhibitors

Cholinesterase inhibitors are the most widely prescribed medications for AD. These drugs, including donepezil, rivastigmine, and galantamine, work by increasing the levels of acetylcholine in the brain, a neurotransmitter involved in memory and cognition. Cholinesterase inhibitors can modestly improve cognitive function, enhance activities of daily living, and temporarily stabilize symptoms in some patients.[35]

7.1.2 NMDA Receptor Antagonist

Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is another pharmacological option for AD. It works by regulating the activity of glutamate, an excitatory neurotransmitter that is excessively released in AD. Memantine helps to moderate glutamate signaling and may slow cognitive decline in moderate to severe AD.[36]

7.1.3 Combination Therapy

In certain situations, doctors may prescribe cholinesterase inhibitors and memantine together for better results. Using these medications together can improve cognitive abilities, overall performance, and daily activities more effectively than just one alone.[37]

7.2 Non-pharmacological Interventions

7.2.1 Cognitive Stimulation

Cognitive Stimulation Cognitive stimulation involves activities that keep the brain active and can help maintain cognitive function in people with Alzheimer's (AD). These activities include puzzles, memory games, computer programs, and other challenges for the mind.[38]

7.2.2 Physical Exercise

Physical Exercise Regular exercise, like walking or swimming, has shown promise in improving cognitive function and slowing down AD progression. It can increase brain volume, improve memory, and enhance cognitive performance.[39]

7.2.3 Social Engagement

Social Engagement Staying socially connected and participating in social activities can positively impact cognition and emotional well-being. This may involve joining support groups, volunteering, or participating in community activities.[40]

7.2.4 Caregiver Education and Support

Caregiver Education and Support Providing education and support to caregivers is crucial for managing the challenges of AD. Caregiver interventions offer information about the disease, coping strategies, stress management techniques, and connections to support networks.[41]

7.3 Future Directions

Current treatments provide some benefits but mainly address symptoms without modifying the underlying disease process. Researchers are exploring new approaches and targets for intervention.

7.3.1 Disease-Modifying Therapies

Ongoing clinical trials investigate various therapeutic interventions to modify the pathological processes underlying Alzheimer's disease (AD). These treatments specifically target key processes implicated in AD, such as mitigating the accumulation of detrimental substances or attenuating neuroinflammation within the brain.[42]

7.3.2 Precision Medicine

Precision medicine endeavors to tailor treatment strategies based on an individual's unique genetic profile, biomarkers, and disease stage. This personalized approach enables the identification of distinct subtypes of AD or divergent patterns of disease manifestation, thus facilitating customized interventions.[43]

7.3.3 Combination Therapies

Given the intricate nature of AD, combining therapeutic agents that concurrently target multiple pathological processes may prove more efficacious than singularly focused treatments. For instance, combining drugs designed to counteract amyloid accumulation with those addressing inflammation or tau pathology holds the potential for synergistic benefits.[44]

7.3.4 Lifestyle Modifications

Mounting evidence suggests that lifestyle modifications can significantly mitigate the risk of AD or slow its progression. These modifications encompass adopting a nutritious diet rich in fruits and vegetables, engaging in regular physical exercise, managing cardiovascular risk factors, nurturing social connections, and participating in mentally stimulating activities.[45]

8. Emerging Therapies and Future Directions

The search for effective treatments for Alzheimer's disease (AD) remains an active area of research, with researchers exploring novel approaches and avenues. While current interventions predominantly focus on symptom management, there is a pressing need for therapies capable of modifying the underlying disease process. Recent advances in understanding AD pathophysiology have opened up promising prospects for therapeutic interventions. In this section, we delve into emerging therapies and outline future directions that inspire optimism for the future of AD treatment.[34]

8.1 Immunotherapy

Immunotherapy has emerged as a promising modality to target the fundamental etiological factors underlying AD. Preclinical investigations and early-stage clinical trials have demonstrated the development of specific antibodies that bind to and facilitate removing amyloid-beta (Aβ) plaques from the brain. These antibodies help clear Aβ, reduce plaque build-up, and potentially slow disease progression. Ongoing research is focused on optimizing these antibodies' design, dosage, and administration to improve safety and effectiveness. Another immunotherapy approach involves using vaccines to stimulate the immune system to produce antibodies against Aβ. Although this approach has shown promise in animal models, there are challenges to overcome related to potential side effects and personalized treatments. Nevertheless, ongoing research aims to refine active immunization strategies for safe and effective outcomes.[46]

8.2 Gene Therapy

Gene therapy holds great potential in treating AD by targeting genetic factors associated with the disease. One approach involves using viral vectors to deliver therapeutic genes to the brain, aiming to enhance neuronal function or reduce the accumulation of toxic proteins. For example, modifying the expression of the brain-derived neurotrophic factor (BDNF) gene, which is involved in neuronal survival and plasticity, has shown positive effects in animal models of AD. Reduced generation or increased clearance of amyloid-beta (Aβ) is another strategy used in gene therapy for Alzheimer's disease (AD). To treat Alzheimer's disease (AD), researchers are actively investigating gene therapy, which involves altering genes related to Aβ transport or metabolism. This strategy aims to lower brain Aβ levels and may impede the advancement of the illness. Current research endeavors center on enhancing safety protocols, refining delivery systems, and tackling obstacles associated with accurate gene targeting and enduring consequences.[47]

8.3 Stem Cell Therapy

One promising regenerative therapeutic strategy for Alzheimer's disease (AD) is stem cell therapy. This novel approach entails replacing damaged or degenerated neurons in the brain with specialized cells called stem cells, which aid in regenerating neural connections and enhancing cognitive performance. Neural stem cells induced pluripotent stem cells (iPSCs), and embryonic stem cells are some sources from which stem cells can be obtained. Experiments using animal models of AD have shown promising results after stem cell transplantation, including improved cognitive performance, and increased neural connections. Still, several important issues must be resolved before clinical viability is achieved. These challenges encompass ensuring the differentiation of transplanted stem cells into functional neurons, circumventing immune rejection responses, and navigating ethical considerations associated with the use of embryonic stem cells. Ongoing research endeavors focus on refining transplantation techniques, exploring strategies to enhance the survival and integration of transplanted cells within existing neural circuits, and investigating this therapeutic modality's long-term safety and efficacy.[48,49]

9. Prevention Strategies

As the prevalence of AD increases, prevention strategies become increasingly important. While there is no guaranteed way to prevent AD, evidence suggests that certain lifestyle modifications and managing risk factors can reduce the risk or delay onset. Regular physical exercise, such as brisk walking or swimming, promotes cardiovascular health and brain function. Adopting a healthy diet, like the Mediterranean diet, rich in fruits, vegetables, whole grains, and healthy fats, is beneficial. Engaging in mentally stimulating activities throughout life, like reading or puzzles, helps maintain cognitive function and may lower the risk of AD.[50]

10. CONCLUSION

To summarize, this article gives a detailed overview of Alzheimer's disease (AD), including how it develops, the factors that increase the risk, how it is diagnosed, the current treatments available, new potential treatments, and strategies to prevent the disease. By understanding the various factors involved in AD and taking preventive actions, we can work towards reducing the impact of this difficult condition. Ongoing research and advancements in treatment options are important for better outcomes for individuals affected by AD.

REFERENCES

1. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer disease, 2018.
2. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jaskirat Sidhu declares no relevant financial relationships with ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. Disclosure: Jack Tsao declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC., 2023.
3. Mohammed AA, Sonawane KD. Destabilizing Alzheimer's Aβ42 protofibrils with oleocanthal: In-silico approach. BIOINFOLET-A Quarterly Journal of Life Sciences, 2022; 19(3): 288-95.
4. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 2020; 25(24).
5. Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Translational Neurodegeneration, 2018; 7(1): 2.

6. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther, 2022; 7(1): 272.
7. Hippius H, Neundörfer G. The discovery of Alzheimer's disease. Dialogues Clin Neurosci, 2003; 5(1): 101-8.
8. Yang HD, Kim DH, Lee SB, Young LD. History of Alzheimer's Disease. Dement Neurocogn Disord, 2016; 15(4): 115-21.
9. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med, 2016; 8(6): 595-608.
10. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol, 2010; 23(4): 213-27.
11. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med, 2012; 2(4): a006213.
12. Arafah A, Khatoon S, Rasool I, Khan A, Rather MA, Abujabal KA, et al. The Future of Precision Medicine in the Cure of Alzheimer's Disease. Biomedicines, 2023; 11(2).
13. Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord, 2011; 25(3): 187-95.
14. Wong W. Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care, 2020; 26(8 Suppl): S177-s83.
15. Roehr S, Pabst A, Luck T, Riedel-Heller SG. Is dementia incidence declining in high-income countries? A systematic review and meta-analysis. Clin Epidemiol, 2018; 10: 1233-47.
16. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther, 2016; 8(1): 23.
17. Murphy MP, LeVine H, 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis, 2010; 19(1): 311-23.
18. Mohammed AA, Barale SS, Kamble SA, Paymal SB, Sonawane KD. Molecular insights into the inhibition of early stages of Aβ peptide aggregation and destabilization of Alzheimer's Aβ protofibril by dipeptide D-Trp-Aib: A molecular modelling approach. International Journal of Biological Macromolecules, 2023; 242: 124880.
19. Weggen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res Ther, 2012; 4(2): 9.
20. Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther, 2011; 17(5): 514-24.
21. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci, 2015; 18(6): 800-6.
22. Cai Y, Liu J, Wang B, Sun M, Yang H. Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets. Front Immunol, 2022; 13: 856376.
23. Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst), 2017; 7: 69-87.
24. Iqbal K, Grundke-Iqbal I. Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement, 2010; 6(5): 420-4.
25. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med, 2012; 2(10).

26. Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function. Curr Alzheimer Res, 2016; 13(11): 1200-7.
27. Kilian J, Kitazawa M. The emerging risk of exposure to air pollution on cognitive decline and Alzheimer's disease - Evidence from epidemiological and animal studies. Biomed J, 2018; 41(3): 141-62.
28. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Cmaj, 2006; 174(6): 801-9.
29. Mahalakshmi B, Maurya N, Lee SD, Bharath Kumar V. Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration. Int J Mol Sci, 2020; 21(16).
30. Albert MS. Changes in cognition. Neurobiol Aging, 2011; 32 Suppl 1(0 1): S58-63.
31. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration, 2019; 14(1): 32.
32. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. The Journal of Prevention of Alzheimer's Disease, 2021; 8(3): 371-86.
33. Neugroschl J, Wang S. Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med, 2011; 78(4): 596-612.
34. Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis, 2020; 12: 1179573520907397.
35. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. Curr Ther Res Clin Exp, 2003; 64(4): 216-35.
36. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res, 2012; 9(6): 746-58.
37. Alugoju P, Krishna Swamy VKD, Anthikapalli NVA, Tencomnao T. Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review. Crit Rev Food Sci Nutr, 2022: 1-66.
38. Schultz SA, Larson J, Oh J, Koscik R, Dowling MN, Gallagher CL, et al. Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. Brain Imaging Behav, 2015; 9(4): 729-36.
39. Pahlavani HA. Exercise therapy to prevent and treat Alzheimer's disease. Front Aging Neurosci, 2023; 15: 1243869.
40. Carstensen LL, Hartel CR, Council NR. Social Engagement and Cognition. When I'm 64: National Academies Press (US); 2006.
41. Reinhard SC, Given B, Petlick NH, Bemis A. Supporting family caregivers in providing care. Patient safety and quality: An evidence-based handbook for nurses, 2008.
42. Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, García-Morales V, García-Cozar FJ, Ramos-Rodríguez JJ, et al. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. Pharmaceutics, 2022; 14(6).
43. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D'Agostino Y, Salvati A, et al. Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease. Genes (Basel), 2020; 11(7).

44. Salloway SP, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, et al. Advancing combination therapy for Alzheimer's disease. Alzheimers Dement (N Y), 2020; 6(1): e12073.
45. Bhatti GK, Reddy AP, Reddy PH, Bhatti JS. Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease. Front Aging Neurosci, 2019; 11: 369.
46. Counts SE, Lahiri DK. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. Curr Alzheimer Res, 2014; 11(7): 623-5.
47. Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GE, Cruz-Martins N, et al. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol, 2022; 59(1): 191-233.
48. Sivandzade F, Cucullo L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int J Mol Sci, 2021; 22(4).
49. Qin C, Li Y, Wang K. Novel Balance Mechanism Participates in Stem Cell Therapy to Alleviate Neuropathology and Cognitive Impairment in Animal Models with Alzheimer's Disease. Cells, 2021; 10(10).
50. Scalco MZ, van Reekum R. Prevention of Alzheimer disease. Encouraging evidence. Can Fam Physician, 2006; 52(2): 200-7.